CARGO: advancing chimeric antigen receptor T cell therapy using nanobody-displaying lentiviral vectors.
Description: Research into adoptive T cell therapy for cancer is trending. Herein, the focus lies on chimeric antigen receptor engineered T (CAR-T) cells as evidenced by over 100 companies investing in CAR-T cell technology. This is explained by the success achieved by CAR-T cells in hematological malignancies. However, similar results have not been obtained in the context of solid tumors. Among the top priorities to develop an affordable and effective CAR-T cell therapy for solid tumors is simplifying the CAR-T cell manufacturing process and improving the design of the CAR as well as the armor of the T cell. In the CARGO-project, we will work on these aspects, building on innovative technologies developed at the VUB, in particular nanobodies (Nbs), to develop T cell-targeted Nb-displaying lentiviral vectors (LVs) harboring Nb-engineered CARs (nanoCARs) and when required factors that enhance T cell homing, tumor infiltration and functionality. We will study LVs displaying cross-reactive CD3-, CD4- or CD8-targeted Nbs that harbor T cell enhancing factors in addition to nanoCARs directed against HER2. We will study these LVs using breast cancer spheroids generated with HER2+ cells of human or mouse origin as well as in immunocompetent mouse models. The latter will provide an in-depth preclinical analysis of the potential of the in vivo nanoCAR-T cell approach, and as such will open the path to clinical translation.
Funder: Fonds Wetenschappelijk Onderzoek
Funding type: grant
Funder scheme: FWO Strategic Basic Research Grant
Start date: 2020-11-01
End date: 2022-10-31
Investigators: Fien Meeus (lead), Nick Devoogdt (co-lead)
Institutions: Research Foundation - Flanders, FWO
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 1
Funder award ID: 1S68521N
OpenAlex ID: G7745859898
